Aavivo, Inc.

What Aavivo, Inc. does

AAVivo, Inc. is a Houston, Texas-based clinical-stage biotechnology company that develops AAV-based in vivo gene therapies for cancer. The company was spun off from Virovek Inc. in 2025 and registered as a Delaware Corporation, with operations currently funded entirely by Virovek as its sole investor.

The company's core offering is its proprietary IntelligentAAV (iAAV) platform, which integrates four technology modules: BAC-to-AAV manufacturing (for high-yield, clinical-grade vector production at large scale), Precision AAV Capsid Engineering (PACE) for selective in vivo cell targeting (including T Cell Targeting Technology / TCeT, Selective Toxin Packaging / SToP, and Tri-Specific T-Cell Engager / TriTE), a microRNA Safety Shield to limit off-target toxicity, and the ToxinSwitch safety-switchable payload system. Built on this platform, AAVivo is advancing three programs: AVO-100 (Enhance) targeting hematologic malignancies, AVO-200 (Kill) targeting solid tumors, and AVO-300 (Redirect) for in situ redirection of cells in solid tumors. AAVivo holds exclusive worldwide rights to Virovek's patented BAC-to-AAV technology (US8945918B2).

AAVivo is pre-revenue and not yet commercialized. Its revenue model is implicit and forward-looking: future revenue would derive from eventual commercialization of its therapeutic candidates, likely through traditional pharmaceutical distribution channels or partnership / out-licensing arrangements with larger biopharma companies. The company reaches its audience today through scientific conference presentations (ASGCT, SITC, BIOHK) and a dedicated investor relations page; named customers and end-user segments in the source material are characterized by indication (hematologic malignancy and solid tumor patients) rather than by paying commercial accounts.

Name

Aavivo, Inc.

Legal name

AAVivo, Inc.

Website

https://aavivo.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

AAVivo, Inc. is a Houston-based, clinical-stage biotechnology company spun off from Virovek in 2025 that develops in vivo AAV gene therapies for cancer using its proprietary IntelligentAAV (iAAV) platform spanning AVO-100 (hematologic malignancies) and AVO-200/AVO-300 (solid tumors).

Ownership category

akta.pro rank

Product category

In vivo AAV gene therapy (oncology biologics)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

akta.pro secondary industry

AAV Vector Gene Therapy Developers (HLAAACAA)

Keywords

• In vivo gene therapy
• AAV-based biotherapeutics
• Cancer cell therapy
• Hematologic malignancy therapy
• Solid tumor gene therapy

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pre-revenue / Virovek Funded: AAVivo is currently pre-revenue. All company activities are funded by Virovek Inc., the parent company from which AAVivo was spun off. The company is not yet commercialized and is focused on advancing clinical programs.

Marketing channels2 records

Core offering

AAVivo is a clinical-stage biotechnology company developing precision-targeted in vivo AAV-based gene therapies for cancer. Its core offering is the IntelligentAAV (iAAV) platform, which enables therapeutic payloads to be produced directly inside the patient's body, avoiding the complex ex vivo manufacturing required by conventional CAR-T therapies. The company is advancing three clinical programs — AVO-100 for hematologic malignancies, and AVO-200 and AVO-300 for solid tumors.

Product overview

Aavivo, Inc. is a biotechnology company offering a unified product ecosystem centered on its proprietary IntelligentAAV (iAAV) platform. The iAAV platform integrates four core technology modules: BAC-to-AAV (manufacturing), PACE (capsid engineering), miRNA Safety Shield (safety), and ToxinSwitch (payload control). Built on this platform, the company is advancing three clinical programs: AVO-100 for hematologic malignancies, AVO-200 for solid tumors (Kill), and AVO-300 for solid tumors (Redirect). The technology portfolio includes sub-modules such as TCeT, SToP, and TriTE for specialized targeting and payload delivery. The company spun off from Virovek and holds exclusive worldwide rights to Virovek's patented BAC-to-AAV technology.

Differentiator

Problem solved

Functional benefit

Products and services

• iAAV (IntelligentAAV) Platform A proprietary integrated platform for in vivo AAV gene therapy enabling direct delivery of therapies inside the patient's body. It combines BAC-to-AAV manufacturing, PACE capsid targeting, a microRNA Safety Shield, and ToxinSwitch payload control to enable precision-targeted cancer biotherapeutics that can be produced in situ without ex vivo manufacturing.
• AVO-100 Flagship AAV-based gene therapy program designed to enhance immune cell function in hematologic malignancies, including leukemias and lymphomas, via in vivo AAV delivery enabled by the iAAV platform.
• AVO-200 AAV-based gene therapy program for solid tumors using a Kill therapeutic approach that delivers selectively activatable toxin payloads to malignant cells via the iAAV platform.
• AVO-300 AAV-based gene therapy program for solid tumors using a Redirect therapeutic approach that instructs target cells in situ to produce targeted therapies locally and persistently, minimizing systemic exposure.

Quantifiable outcome

• In vivo AAV-based therapies capable of delivering diverse payloads to specific tissues or cell types

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Voyager Therapeutics: Voyager is an AAV gene therapy company developing CNS-targeted therapies using engineered capsids. Comparable through its emphasis on precision capsid engineering, parallel to AAVivo's PACE platform approach.
• uniQure: uniQure is a clinical-stage AAV gene therapy company with approved and pipeline assets across hemophilia, Huntington's disease, and other indications. Comparable as an incumbent AAV gene therapy developer facing similar class-level safety, manufacturing, and regulatory dynamics.
• Regenxbio: Regenxbio is an established AAV gene therapy platform company with multiple clinical-stage programs and licensed AAV capsid technology used across the industry. Comparable as a broad AAV platform incumbent whose capsid IP and manufacturing tools overlap with AAVivo's PACE and BAC-to-AAV technologies.
• Krystal Biotech: Krystal Biotech is a commercial-stage AAV gene therapy company with an FDA-approved product (Vyjuvek) and a dermatology/cardiopulmonary pipeline. Comparable as a direct AAV gene therapy competitor demonstrating clinical and commercial proof-of-concept for the modality.
• Sarepta Therapeutics: Sarepta is a leading commercial-stage AAV gene therapy company with multiple approved products in muscular dystrophy. Comparable as a broad incumbent in AAV gene therapy commercialization, manufacturing, and regulatory navigation.

Direct peers

• Umoja Biopharma: Umoja is developing in vivo cell therapy platforms that reprogram immune cells inside patients, including in vivo CAR-T candidates. It pursues a similar therapeutic premise to AAVivo — bypassing ex vivo manufacturing — and competes for the same hematologic and solid tumor indications.
• Capstan Therapeutics: Capstan is developing in vivo CAR-T therapies using lipid nanoparticle delivery of mRNA payloads to engineer T cells inside the patient. It is the most directly comparable strategic competitor to AAVivo's in vivo CAR-T approach via a different delivery modality (LNP vs AAV).
• Eso Biotherapeutics: Eso is developing an in vivo CAR-T platform using lentiviral delivery to reprogram T cells directly in patients. Closely comparable to AAVivo's in vivo CAR-T thesis, with overlapping target indications in hematologic malignancies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/aavivo

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aavivo, Inc.